Global CAR-T Cell Therapy Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 34% during forecast period.
Global CAR-T Cell Therapy Market Overview:
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is a type of cell-based gene therapy it involves altering the genes inside T cells to help them attack cancer.
Global CAR-T Cell Therapy Market Dynamics:
Rising prevalence of cancer coupled with high demand for effective treatment to cure cancer is driving the market growth.
Recent studies suggest that over 1.7 million new cancer patients are recorded in U.S. alone and nearly 4.3 million in China. A rising number of adults and children developing cancer is expected to increase demand for effective and reliable therapeutic treatment approach for the improvement of the quality of patient’s lives.
Moreover, the development of new and effective therapy options to cure symptoms of the disease is also contributing to the growth of the CAR-T cell therapy market. Increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling the growth of the market. In December 2016, the National Cancer Advisory Board authorized US$ 1.8 Bn in funding for Cancer Moonshot, which is an initiative taken up to accelerate research with an aim to make more therapies available to patients with cancer. However, High costs associated with CAR-T therapy and lack of cost-effective therapies for cancer have influenced the health conditions of the population and have led to a low average life expectancy. These factors may hinder the market growth.
The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology is analyzed and report has come up with recommendations for future hot spot in APAC region.
Global CAR-T Cell Therapy Market Segment Analysis:
The global CAR-T Cell Therapy market is segmented on the basis of Target Antigen, Therapeutic Application and End-Users.
Based on Target Antigen, CD19/CD22 target antigens are estimated to hold the largest market share. The strong growth is creditable to the high approval rate of the antigens and their commercialization. On the other hand, BCMA (B-cell maturation antigen) segment is anticipated to record a robust growth rate growth over the forecasted years.
Global CAR-T Cell Therapy Market
To know about the Research Methodology :- Request Free Sample Report
Based on Therapeutic Application, diffuse large B-cell lymphoma is expected to dominate the global market. It accounted for 56.1% of the total market share in 2019. The Multiple Myeloma (MM) segment is expected to register a significant growth rate over the forecast period.
Global CAR-T Cell Therapy Market Regional Insights:
Global CAR-T Cell Therapy Market 1
North America is expected to dominate global market over forecast years.
North America’s market growth is attributed due to the rapid development and launch of new therapies for the treatment of cancer by key players in the market. For instance, in August 2017, the U.S. Food and Drug Administration (FDA) approved Kymriah, a CAR-T cell therapy to treat pediatric and young adult patients suffering from a form of acute lymphoblastic leukemia. Moreover, a large patient pool suffering from cancer in the U.S. and Canada is expected to further fuel the growth of the region in the global market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2016, around 171,000 patients with blood cancer are diagnosed each year in the U.S. Europe is expected to hold the second-largest market during the forecast period.
Asia Pacific is expected to witness lucrative growth during forecast period.
Asia Pacific is expected to exhibit the highest growth over the forecast period, owing to the increasing number of global players collaborating and signing research as well as manufacturing contracts for CAR-T cell therapies with local players in the region. For instance, Cesca Therapeutics signed a license agreement with China-based, Boyalife Group, in March 2018, for CAR-T cell-related bioprocessing, development, and manufacturing outsourcing.
The report also helps in understanding Global CAR-T Cell Therapy Market dynamics, structure by analyzing the market segments and project the Global CAR-T Cell Therapy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global CAR-T Cell Therapy Market make the report investor’s guide.
Global CAR-T Cell Therapy Market, Key developments:
• In February 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb company. Breyanzi is approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
• In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma’s brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL). The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.
For More Information Visit @:
Global CAR-T Cell Therapy Market Scope: Inquire before buying
Global CAR-T Cell Therapy Market 2
Global CAR-T Cell Therapy Market, by Region:
• North America
• South America
Global CAR-T Cell Therapy Market, Key player:
• Gilead Sciences
• Novartis AG
• Gracell Biotechnology Ltd
• Aeon Therapeutics
• CARsgen Therapeutics
• Daiichi Sankyo
• Otsuka Pharmaceutical
• Ono Pharmaceutical
• Japan Tissue Engineering
• Nipro Corporation
• Takeda Pharmaceutical Company
• Astellas Pharma
• PersonGen Biomedicine
• Hebei Senlang Biotech
• Eli Lilly and Company
• Johnson & Johnson Private Limited
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.